Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on September 3, 2019. The filing addresses corporate governance changes under Item 5.02 regarding the departure, election, and appointment of directors, as well as compensatory arrangements for new board members.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition and director compensation rather than financial performance.
Material Changes
- Board Reshuffling: To comply with the Company's Charter requiring nearly equal numbers of directors in each class, John Kennedy resigned as a Class II director and was immediately re-elected as a Class III director effective September 3, 2019.
- New Director Election: The Board elected Alan Edrick as an additional Class III director. Mr. Edrick is an independent director expected to serve until the 2021 annual meeting.
- Committee Assignments: Mr. Kennedy continues as Chairman and member of the Audit and Compensation Committees. Mr. Edrick is expected to be appointed to the Audit and Compensation Committees.
Guidance, Outlook, and Compensation Details
The filing details specific compensatory arrangements for the newly elected director, Alan Edrick, effective September 10, 2019:
- Stock Options: Mr. Edrick will receive a non-qualified stock option to acquire shares equal to the greater of options with an aggregate Black-Scholes cash value of $134,400 or 25,000 shares. These options have a 10-year term and vest in three equal installments over three years.
- Deferred Stock Award: In lieu of cash retainer compensation for the remainder of 2019, Mr. Edrick will receive restricted stock units (RSUs) vesting on December 31, 2019. The share count is calculated based on the cash retainer amount divided by the average daily closing market price for July.
The filing does not contain management commentary on financial outlook, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the exact number of shares granted to Alan Edrick once the July average stock price is applied to the RSU calculation.
- Confirm the specific vesting schedule dates for the stock options granted to Mr. Edrick.
- Review the attached press release (Exhibit 99.1) for any additional context on the strategic rationale for the board changes.
- Check subsequent filings for the formal appointment of Mr. Edrick to the Audit and Compensation Committees.